New users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors had about half the risk of an ED visit or hospitalization for a gout flare as matched patients taking dipeptidyl peptidase-4 inhibitors, a cohort analysis found.
11 Aug 2023
Analysis of a randomized trial in South Korea found that patients randomized to rosuvastatin developed type 2 diabetes requiring medication at a rate of 7.2%, compared to 5.3% among those given atorvastatin.
10 Nov 2023
Peak diagnosis age was approximately 15 years, and the median age of diagnosis was 24 years, but 37% of adults with type 1 diabetes reported having been diagnosed after age 30 years in a recent study.
13 Oct 2023
A subgroup analysis of a randomized trial found that patients with diabetes and atherosclerotic cardiovascular (CV) disease had similar outcomes whether they took 81 mg or 325 mg of aspirin daily.
13 Oct 2023
In a retrospective cohort study, people with an evening chronotype were more likely to smoke, sleep poorly, and be physically inactive and had a 72% higher risk for diabetes than those with a morning chronotype.
13 Oct 2023
The World Health Organization (WHO) cited a lack of evidence suggesting that short-term use of nonsugar sweeteners affected body weight or other measures of adiposity, as well as possible long-term undesirable effects on noncommunicable diseases and death.
9 Jun 2023
The latest Pearls from I.M. Peers offers advice on prescribing glucagon-like peptide-1 (GLP-1) receptor agonists for patients with diabetes.
10 Mar 2023
High-certainty evidence indicated that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists reduce all-cause death, while finerenone probably also reduced mortality based on moderate-certainty evidence.
12 May 2023
An industry-funded study of patients age 75 years and older who were taking insulin for type 2 diabetes found that almost two-thirds (65.2%) experienced nocturnal hypoglycemia during a 28-day study period.
14 Apr 2023
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
11 Nov 2022